In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.
“We’re using a cell as a reaction vessel and a disease-causing defect as a catalyst to synthesize a treatment in a diseased cell,” said TSRI Professor Matthew Disney. “Because the treatment is synthesized only in diseased cells, the compounds could provide highly specific therapeutics that only act when a disease is present. This means we can potentially treat a host of conditions in a very selective and precise manner in totally unprecedented ways.”
The promising research was published recently in the international chemistry journal Angewandte Chemie.
Targeting RNA Repeats
In general, small, low molecular weight compounds can pass the blood-brain barrier, while larger, higher weight compounds tend to be more potent. In the new study, however, small molecules became powerful inhibitors when they bound to targets in cells expressing an RNA defect, such as those found in myotonic dystrophy.
Myotonic dystrophy type 2, a relatively mild and uncommon form of the progressive muscle weakening disease, is caused by a type of RNA defect known as a “tetranucleotide repeat,” in which a series of four nucleotides is repeated more times than normal in an individual’s genetic code. In this case, a cytosine-cytosine-uracil-guanine (CCUG) repeat binds to the protein MBNL1, rendering it inactive and resulting in RNA splicing abnormalities that, in turn, results in the disease.
In the study, a pair of small molecule “modules” the scientists developed binds to adjacent parts of the defect in a living cell, bringing these groups close together. Under these conditions, the adjacent parts reach out to one another and, as Disney describes it, permanently hold hands. Once that connection is made, the small molecule binds tightly to the defect, potently reversing disease defects on a molecular level.
“When these compounds assemble in the cell, they are 1,000 times more potent than the small molecule itself and 100 times more potent than our most active lead compound,” said Research Associate Suzanne Rzuczek, the first author of the study. “This is the first time this has been validated in live cells.”
The Latest on: Specific therapeutics
via Google News
The Latest on: Specific therapeutics
- Oncternal Therapeutics' (ONCT) CEO Jim Breitmeyer on Q2 2020 Results - Earnings Call Transcripton August 8, 2020 at 6:39 am
Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Richard Vincent – Chief Financial Officer Jim Breitmeyer – President & Chief Executive Officer Frank Hsu – Chief Medical ...
- PTC Therapeutics Looks Like A Better Value After Recent Pullbackon August 8, 2020 at 3:58 am
PTC has continued to execute, and the company still showed modest sales growth despite the pandemic. Since my April article on the company, PTC has gotten risdiplam approved and acquired a late-stage ...
- Biologic Therapeutics Drugs Market SWOT Analysis of Top Key Player & Forecasts To 2026on August 7, 2020 at 2:27 pm
Selbyville, Delaware The Global Biologic Therapeutics Drugs Market Report includes a comprehensive analysis of ...
- Jounce Therapeutics, Inc. (JNCE) Q2 2020 Earnings Call Transcripton August 7, 2020 at 10:12 am
Good morning, and welcome to the Jounce Therapeutics' second quarter conference call. This morning, we issued a press release which outlines the topics that we plan to discuss today. The release is ...
- Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updateson August 6, 2020 at 1:19 pm
SIVEXTRO® adds revenue generating product creating additional scale and synergies- -Relaunch of XENLETA® and SIVEXTRO planned with targeted in-person promotion- -Conference call today at 4:30 p.m.
- Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conferenceon August 6, 2020 at 5:15 am
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that manageme ...
- Maverick Therapeutics Announces First Peer-Reviewed Publication Describing the Design and Development of the COBRA™ Platformon August 6, 2020 at 5:00 am
Maverick Therapeutics, Inc., a private biopharmaceutical company pioneering conditionally active bispecific T cell targeted immunotherapies, today ann ...
- TG Therapeutics to Host Conference Call on Second Quarter 2020 Financial Results and Business Updateon August 6, 2020 at 4:42 am
(GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday August 10, 2020 at 8:30 AM ET to discuss results for the second quarter of 2020 ...
- BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatmenton August 5, 2020 at 3:16 pm
BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, ...
- Depression Therapeutics Market Insights By Size, Share, Future Growth And Forecast From 2020-2029on August 5, 2020 at 6:53 am
The research study on Global Depression Therapeutics market 2019 presents an extensive analysis of current Depression Therapeutics market size, drivers, trends, opportunities, challenges, as well as ...
via Bing News